The 45 day review period is up last week. No news is good news, in this case.
The HUD approval will double NVIV share price.
The 5 patient human trial news sends this off the charts, imo.
If you think $ 5.00 is off the charts,then i'm glad you don't work for me...
Sentiment: Strong Buy
Personally, I would have preferred good news over no news, but no news is definitely better than bad news.
We continue to wait. If HUD status is given, it's higher from here. Approval for trials to start and we should see $4+